Melodiol Global's Mernova Unit Launches More Products; Shares Jump 50%
Cannabis-focused company Melodiol Global Health's (ASX:ME1) shares surged 50% on Thursday following the launch of several products by its Canadian subsidiary Mernova, as well as new purchase orders. M
Melodiol Global Health Subsidiary Health House Australia to Launch Medicinal Cannabis Clinic
Melodiol Global Health (ASX:ME1), through its subsidiary Health House Australia, is set to launch its medicinal cannabis clinic called the Health House Wellness Clinic in the second quarter of 2024, a
Melodiol Global Health Posts 148% Increase in FY 2023 Revenue to AU$21.6 Million
Melodiol Global Health (ASX:ME1) has posted unaudited revenues of AU$3.1 million through February and ongoing total unaudited group revenue from all operations of AU$21.6 million in the 2023 financial
Melodiol Unit to Add Cannabis Products Across Six Canadian Provinces
Melodiol Global Health's (ASX:ME1) Canadian subsidiary Mernova Medicinal reached agreements with six provincial governments in Canada to add more cannabis-related products during the first fiscal quar
Melodial's Unit Logs AU$1 Million Revenues in January
Melodiol Global Health (ASX:ME1) said its unit Health House International reported a revenue of AU$1 million in January. The revenue was generated from the medicinal cannabis company's established Aus
Melodiol Global's Canadian Arm Mernova Posts Record Sales for October
Melodiol Global Health (ASX:ME1) said Canadian subsidiary Mernova Medicinal has secured several purchase orders to "underpin" fiscal fourth-quarter revenue. The firm also said that the unit logged rec
Melodiol Global Health Achieves 80% Remission Rate From Phase Two Hallucinogenic Trial
Melodiol Global Health (ASX:ME1) achieved an 80% remission rate from the first five patients treated in its phase two trial investigating the efficacy of the medical cannabis firm's Lucenex medication
Melodial's Canadian Arm Mernova Logs Record Sales in Q3
Melodial Global Health (ASX:ME1) said Canadian subsidiary Mernova Medicinal logged its third consecutive quarter of growth during the three-month period ended Sep. 30, and logged a record revenue of r
Melodiol Logs Strong Start to Q3 With AU$1.6 Million in Revenue and Confirmed Purchase Orders
Melodiol Global Health (ASX:ME1) is seeing a strong start to the third quarter of 2023 as it has already booked AU$1.6 million in new unaudited revenue and confirmed purchase orders as of July 17. The
Express News | Melodiol Global Health Triples Q2 Net Sales
No Data